Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Van Eeden, Ronwyn![]() |
|
dc.contributor.author | Rapoport, Bernardo Leon![]() |
|
dc.contributor.author | Smit, Teresa![]() |
|
dc.contributor.author | Anderson, Ronald![]() |
|
dc.date.accessioned | 2020-01-31T04:54:08Z | |
dc.date.available | 2020-01-31T04:54:08Z | |
dc.date.issued | 2019-07-24 | |
dc.description.abstract | Nivolumab (PD-1 inhibitor) and other immune checkpoint inhibitors are used primarily to promote reactivation of anti-tumor immunity. However, due to their generalized immunorestorative properties, these agents may also trigger an unusual spectrum of side-effects termed immune-related adverse events. In the case of the lung, pulmonary infiltrates in patients treated with the anti-PD-1 inhibitors, nivolumab, or pembrolizumab, especially patients with non-small cell lung cancer, can result from immune-related pneumonitis, which, until fairly recently was believed to be of non-infective origin. This, in turn, may result in progression and pseudo-progression of disease. An increasing body of evidence has, however, identified pulmonary tuberculosis as an additional type of anti-PD-1 therapy-associated, immune-related adverse event, seemingly as a consequence of excessive reactivation of immune responsiveness to latentMycobacteriumtuberculosis infection. The current case report describes a 56-year old Caucasian female who presented with microbiologically-confirmed tuberculosis infection while on nivolumab therapy for non-small cell lung cancer. Notably, the patient, seemingly the first described from the African Continent, had not received immunosuppressive therapy prior to the diagnosis of tuberculosis. | en_ZA |
dc.description.department | Immunology | en_ZA |
dc.description.librarian | am2020 | en_ZA |
dc.description.uri | http://www.frontiersin.org/Oncology | en_ZA |
dc.identifier.citation | van Eeden R, Rapoport BL, Smit T and Anderson R (2019) Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review. Frontiers in Oncology 9:659. DOI: 10.3389/fonc.2019.00659 | en_ZA |
dc.identifier.issn | 2234-943X (online) | |
dc.identifier.other | 10.3389/fonc.2019.00659 | |
dc.identifier.uri | http://hdl.handle.net/2263/73040 | |
dc.language.iso | en | en_ZA |
dc.publisher | Frontiers Media | en_ZA |
dc.rights | © 2019 van Eeden, Rapoport, Smit and Anderson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). | en_ZA |
dc.subject | Checkpoint inhibitors | en_ZA |
dc.subject | Non-small cell lung cancer | en_ZA |
dc.subject | Pulmonary infiltrates | en_ZA |
dc.subject | Immune reconstitution | en_ZA |
dc.subject | Tuberculosis (TB) | en_ZA |
dc.subject | Nivolumab | en_ZA |
dc.subject | Lung cancer | en_ZA |
dc.title | Tuberculosis infection in a patient treated with Nivolumab for non-small cell lung cancer : case report and literature review | en_ZA |
dc.type | Article | en_ZA |